Summit Therapeutics Inc. Files 8-K: Leadership and Compensation Changes
Ticker: SMMT · Form: 8-K · Filed: Apr 11, 2024 · CIK: 1599298
| Field | Detail |
|---|---|
| Company | Summit Therapeutics Inc. (SMMT) |
| Form Type | 8-K |
| Filed Date | Apr 11, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-compensation
TL;DR
Summit Therapeutics filed an 8-K on 4/11/24 for director/officer changes and compensation.
AI Summary
On April 11, 2024, Summit Therapeutics Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indicates a shift in leadership and potential adjustments to how key personnel are compensated.
Why It Matters
Changes in a company's board and executive compensation can signal strategic shifts or impact investor confidence.
Risk Assessment
Risk Level: medium — Changes in executive and board composition can indicate internal shifts that may affect future strategy and performance.
Key Players & Entities
- Summit Therapeutics Inc. (company) — Registrant
- April 11, 2024 (date) — Filing Date
FAQ
What specific changes were made to the board of directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' but does not specify the names of individuals departing or being elected in the provided text.
What are the details of the compensatory arrangements for certain officers?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item of information, but the specific details of these arrangements are not included in the provided text.
When was this 8-K report filed?
This 8-K report was filed on April 11, 2024.
What is the principal executive office address for Summit Therapeutics Inc.?
The principal executive offices are located at 601 Brickell Key Drive, Suite 1000, Miami, FL 33131.
What is Summit Therapeutics Inc.'s fiscal year end?
Summit Therapeutics Inc.'s fiscal year ends on December 31.
Filing Stats: 751 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2024-04-11 16:35:11
Key Financial Figures
- $0.01 — ange on Which Registered Common stock, $0.01 par value per share SMMT The Nasdaq Sto
Filing Documents
- smmt-20240411.htm (8-K) — 31KB
- a2024_prx0411xnewdirecto.htm (EX-99.1) — 10KB
- a2024_prx0411xnewdirecto001.jpg (GRAPHIC) — 271KB
- a2024_prx0411xnewdirecto002.jpg (GRAPHIC) — 231KB
- a2024_prx0411xnewdirecto003.jpg (GRAPHIC) — 84KB
- 0001599298-24-000064.txt ( ) — 1005KB
- smmt-20240411.xsd (EX-101.SCH) — 2KB
- smmt-20240411_def.xml (EX-101.DEF) — 14KB
- smmt-20240411_lab.xml (EX-101.LAB) — 25KB
- smmt-20240411_pre.xml (EX-101.PRE) — 15KB
- smmt-20240411_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press release, dated April 11, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. SUMMIT THERAPEUTICS INC. Date: April 11, 2024 By: /s/ Manmeet S. Soni Chief Operating Officer and Chief Financial Officer (Principal Financial Officer)